ARPP21

Across TCGA pan-cancer cohorts, ARPP21 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated ARPP21 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher ARPP21 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARPP21 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

ESCA, SARC, and BLCA are the cancer types where ARPP21 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.223	0.712	<.001	36	view →
SARC	DFS	Median	All	0.181	0.614	.005	6	view →
BLCA	OS	Median	III,IV	0.212	0.656	.002	6	view →
PRAD	DFS	Median	All	0.634	0.887	.027	4	view →
UCEC	DFS	Median	All	0.798	0.628	.027	4	view →
SKCM	DFS	Median	All	0.667	0.205	.013	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LIHC	OS	Median	All	0.105	0.774	.002	3	view →
LUAD	DFS	Median	II,III,IV	1.000	0.404	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

ARPP21–ESCA (OS)

Open the ESCA breakdown →